[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmia-induced-cardiomyopathy-aicm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmia-induced-cardiomyopathy-aicm":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100584969",false,"NCT06896266","Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy","Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy","UNCHAINED-I","Inclusion Criteria:\n\n* Presence of atrial fibrillation or atrial flutter not self-limited.\n* Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \\\u003C50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \\\u003C50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.\n* Signature of informed consent.\n* Ability to understand and accept participation in the study.\n\nExclusion Criteria:\n\n* Refusal of informed consent.\n* Legal or juridical incapacity.\n* Age \\\u003C18 years.\n* Life expectancy less than 1 year.\n* Impossibility of a follow-up of at least 6 months.\n* Presence of a ventricular rate \\>140 beats per minute, limiting the validity of imaging measurements.\n* Presence of known factors causing systolic ventricular dysfunction:\n\n  * Prior cardiomyopathy diagnosis.\n  * Severe mitral or aortic valve disease.\n  * Non-revascularizable ischemic heart disease.\n  * Context of peri-resuscitation cardiopulmonary care.\n  * Abusive alcohol consumption, defined as \\>80 grams of ethanol or \\>7 standard alcoholic beverages per day.\n  * Active treatment with chemotherapeutic agents or radiation therapy to the thorax.\n  * Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.","ALL","18 Years",{"count":19,"type":20},109,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:\n\nI. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?",[25,26,27],"Arrhythmia","Cardiomyopathy","Arrhythmia-induced Cardiomyopathy (AiCM)",[29,30,31,32,33,34],"atrial fibrillation","atrial flutter","heart failure","arrhythmia-induced cardiomyopathy","cardiomyopathy","genetics","RECRUITING","2025-05-09",{"date":38,"type":39},"2025-05-14","ACTUAL",{"date":41,"type":39},"2024-12-01",{"date":43,"type":20},"2026-12",{"name":45,"class":46},"Hospital Universitario 12 de Octubre","OTHER",4,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100490143","NCT05662293","Characterization of Arrhythmia-induced Cardiomyopathy","Arrhythmia-induced Cardiomyopathy - a Prospective Observational Cohort Study","Prospective part\n\nInclusion Criteria:\n\n* Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics\n* Signed study consent\n\nExclusion Criteria:\n\n* Patient's active refusal of the general consent of the University Hospital Basel\n* Age \\\u003C18 years old\n* Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\\>100 bpm, \\\u003C90 systolic BP, evidence of organ dysfunction).\n* Life expectancy \\\u003C1 year (palliative, terminal cancer)\n\nRetrospective part\n\nInclusion Criteria:\n\n* Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Patient's active refusal of the general consent of the University Hospital Basel\n* Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and\u002For need for resuscitation).\n* Patients with life expectancy \\\u003C1 year (palliative, terminal cancer)",{"count":55,"type":20},2700,"The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.",[26,27],[59,60,61,30,62,63],"atrial fibrillation (AF)","supraventricular tachycardia (SVT)","ventricular tachycardia","Major Adverse Cardiovascular Event (MACE)","cardiac arrhythmia","2025-03-03",{"date":66,"type":39},"2025-03-04",{"date":68,"type":39},"2021-06-10",{"date":70,"type":20},"2027-01",{"name":72,"class":46},"University Hospital, Basel, Switzerland",1,""]